- Home
- NXPI vs TAK Comparison
NXPI vs TAK Comparison
Compare NXPI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXPI
- TAK
- Stock Information
- Founded
- NXPI 2006
- TAK 1781
- Country
- NXPI Netherlands
- TAK Japan
- Employees
- NXPI N/A
- TAK N/A
- Industry
- NXPI Semiconductors
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- NXPI Technology
- TAK Health Care
- Exchange
- NXPI Nasdaq
- TAK Nasdaq
- Market Cap
- NXPI 55.3B
- TAK 45.8B
- IPO Year
- NXPI 2010
- TAK N/A
- Fundamental
- Price
- NXPI $209.00
- TAK $14.76
- Analyst Decision
- NXPI Strong Buy
- TAK
- Analyst Count
- NXPI 19
- TAK 0
- Target Price
- NXPI $247.53
- TAK N/A
- AVG Volume (30 Days)
- NXPI 2.6M
- TAK 1.9M
- Earning Date
- NXPI 07-21-2025
- TAK 07-30-2025
- Dividend Yield
- NXPI 1.94%
- TAK 4.01%
- EPS Growth
- NXPI N/A
- TAK N/A
- EPS
- NXPI 9.18
- TAK 0.45
- Revenue
- NXPI $12,323,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- NXPI N/A
- TAK $1.01
- Revenue Next Year
- NXPI $9.00
- TAK $1.04
- P/E Ratio
- NXPI $23.03
- TAK $63.71
- Revenue Growth
- NXPI N/A
- TAK 7.45
- 52 Week Low
- NXPI $148.09
- TAK $12.58
- 52 Week High
- NXPI $296.08
- TAK $15.43
- Technical
- Relative Strength Index (RSI)
- NXPI 52.92
- TAK 46.62
- Support Level
- NXPI $210.42
- TAK $14.86
- Resistance Level
- NXPI $218.01
- TAK $15.42
- Average True Range (ATR)
- NXPI 6.04
- TAK 0.14
- MACD
- NXPI -0.25
- TAK -0.03
- Stochastic Oscillator
- NXPI 59.22
- TAK 9.47
About NXPI NXP Semiconductors N.V.
NXP Semiconductors is a leading supplier of high-performance mixed-signal products. The firm acquired Freescale Semiconductor in 2015 and now has significant market share in the automotive market, where it supplies microcontrollers and analog chips into automotive clusters, powertrains, infotainment systems, and radars. NXP Semiconductors also serves industrial and Internet of Things, mobile, and communications infrastructure.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.